64 results about "Endometrial receptivity" patented technology

The invention provides a method for detecting endometrial receptivity through MST1 and phosphorylated MST1. The method comprises the steps that a human endometrial carcinoma cell line Ishikawa and HEK293T cells are kept and cultured in a 10% FBS and mycillin containing double-antibody DMEM/F12 culture solution; an immunoblotting experiment is carried out; co-immunoprecipitation is carried out; immunohistochemistry is carried out; adjustment of MST1 on the transcriptional activity of HOXA10 is analyzed through chromosome co-immunoprecipitation (ChIP)/PCRs; human choriocarcinoma cell (BeWo) sphere adhering experiments are carried out. According to the method, the expression level of MST1 and MST1 phosphorylation modification in endometrial tissue is detected conveniently and fast, and the receptivity state of the endometrium can be directly reflected.

The subject invention pertains to methods and reagents for the diagnosis of female infertility, prognostic indicators for female infertility, compounds for the treatment of female infertility, compounds and methods for contraception. Methods and compounds are based on the levels of ebaf in endometrial tissue. Methods for diagnosing endometrial receptivity and bleeding function by screening a biological sample such as an endometrial tissue sample, or bodily fluid for the presence of ebaf. A contraceptive compound containing an effective amount of ebaf and a pharmaceutically acceptable carrier. A diagnostic kit for timing contraception containing reagents for screening a sample for the presence of ebaf. A method of treating endometrial irregularities by down-regulating the expression of ebaf.

The present invention provides a method of predicting the probability of a successful pregnancy, either a naturally achieved pregnancy or a pregnancy resulting from an assisted reproductive technology, based on the level of L-selectin ligand expressed by uterine epithelial cells and/or the level of L-selectin expressed by an embryo in vitro. The invention further provides methods of inhibiting cell adhesion between a trophoblast and a uterine epithelial cell. Methods of inhibiting cell adhesion between a trophoblast and a uterine epithelial cell are useful to inhibit pregnancy. The invention further provides methods of assessing in vitro embryo quality. The invention further provides methods of predicting the probability of continued success of a pregnancy during the first 16 weeks of gestation.

The invention relates to a non-invasive diagnostic method of endometrial receptivity which includes collecting and comparing lipid biomarker patterns to reference lipidomic biomarkers, particularly prostaglandins PGE2 and/or PGF2α. The method is especially applicable for determining status fertility of a mammalian female, preferably, a woman.

The invention belongs to the technical field of traditional Chinese medicines, relating to a traditional Chinese medicine composition for improving endometrial receptivity. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 15-20 of epimedium, 10-15 of morindae officinalis, 20-25 of south dodder seed and 15-20 of eucommia. The preparation method of the traditional Chinese medicine composition is as follows: soaking bulk drugs weighed proportionally with clear water; and boiling the cleared bulk drugs for 40-60 minutes to prepare decoction. The traditional Chinese medicine composition can improve the endometrial receptivity, can be used as an adjuvant drug for external fertilization-embryo transplantation, has the advantages of rich drug sources, simple composition, cheap price, precise curative effect and no toxic and side effects, and can treat both principal and secondary aspect of disease.

The invention relates to a method of assessing pregnancy outcome. The inventors investigated endometrial miRNAs associated with pregnancy outcome by studying miRNAs associated with endometrial receptivity, implantation failure and embryo miscarriage. They performed a miRNomic study to find miRNAs that are differentially expressed according to the endometrial receptivity status, compared the endometrial miRNome between receptive patients with negative beta-hCG and receptive patients with positive beta-hCG, and compared the endometrial miRNome between receptive patients with a miscarriage between 8-12 weeks of amenorrhoea and receptive patients with a live birth. They demonstrated miRNA differential expression in endometrial samples according to the pregnancy outcome. Thus, the invention relates to a method of assessing pregnancy outcome of a patient, comprising a step of measuring in a biological sample obtained from said patient the expression level of at least one miRNA selected from the group consisting of miR-455-3p, miR-4423-3p, miR-4445-3p, miR-3128, miR-3201, let-7b-5p, let-7c-5p, miR-4534, miR-214-3p, miR-15b-5p, miR-424-3p, miR-181a-5p, miR-574-3p, miR-92a-3p, miR-320c, let-7d-5p, miR-125a-5p, miR-320a, miR-320b and let-7f-5p.

The present invention relates to a method for assessing the endometrium receptivity of a patient, comprising a step consisting of measuring the expression level of eleven genes in an endometrial biopsy sample obtained from said patient wherein said genes are MFAP5, ANGPTL1, PROK1, NLF2, LAMB3, BCL2L10, CD68, TRPC4, SORCS1, FST and KRT80.

The invention belongs to the field of traditional Chinese medicine and relates to a traditional Chinese medicine compound preparation for improving endometrial receptivity and a preparation method and application thereof. The preparation accords with traditional Chinese medicine treatment principles, and can supplement and condition viscera, qi, blood and channels and collaterals. The traditional Chinese medicine compound preparation for improving endometrial receptivity is prepared from extracts of traditional Chinese medicine materials including prepared rehmannia root, white peony root, fleece-flower root, ligustrum lucidum ait, cornus officinalis, radix ophiopogonis, morinda officinalis, radix codonopsis, rhizoma cyperi and semen cuscutae. The preparation can improve endometrial receptivity, easily simplifies the treatment step of in-vitro fertilization and embryo transfer, namely test tube baby, increases the pregnancy rate and the live birth rate, and builds effective intervening measures combining traditional Chinese medicine and western medicine. The composite preparation can be used for preparing medicine preparations for treating infertility.

The invention discloses construction and identification of immortalized human endometriosis eutopic stromal cells (iheESCs), and relates to endometriosis. The invention relates to the iheESCs construction, and the identification of characteristics of iheESCs cells as endometrial stromal cells. A cell growth cycle of the constructed iheESCs cells is obviously prolonged, a proliferation rate, an estrogen/progesterone receptor, an EMT marker protein and the like are not changed, meanwhile, deciduation induction reaction, estrogen reaction and inflammatory reaction are changed, and the constructedcells do not have tumorigenicity. Therefore, compared with common primary cells, the constructed iheESCs have the characteristics of long growth cycle, stable phenotype and higher state activity, canbe suitable for research on endometriosis pathological mechanisms, endometrial receptive physiological mechanisms and the like, and have certain applicability in clinical experiments, medical biological experiments and the like.

Compositions and methods for determining endometrial receptivity to embryo implantation and for detecting and treating castration-recurrent prostate cancer are provided. The methods comprise measuring the level of melanoma antigen gene protein-11 (MAGE-11, also referred to as MAGE-Al 1) in an endometrial or prostate tissue sample. The level of MAGE-11 protein or mRNA can be correlated to endometrial receptivity to embryo implantation in a female human or nonhuman primate, or to the presence of castration-recurrent prostate cancer in a male patient in need thereof. Methods are described whereby MAGE-11 may serve as a target for vaccine development in the treatment of castration-recurrent prostate cancer. Methods for monitoring endometrial maturation, for diagnosing infertility, and for in vitro fertilization in a female human or nonhuman primate are also provided. Compositions of the invention include antibodies that specifically bind MAGE-11 and oligonucleotide primers useful for detecting MAGE-11 mRNA, as well as kits containing such antibodies or primers.

The invention relates to a reagent kit for assessing endometrial receptivity. The reagent kit comprises gDNA scavenger buffer liquid, a gDNA scavenger, cDNA reverse transcription buffer liquid, a cDNAreverse transcription mixture, a reverse transcription primer mixture, real-time fluorescent quantitation polymerase chain reaction liquid, a probe, a positive control standard product and enzyme-free water. The probe is combined with a target gene through molecular hybridization to generate hybridized signals, so that the target gene in massive genomes can be shown. A specific sequence of reverse transcription products is combined with detection of probe signals, so that expression level of specific genes can be detected, and the endometrial receptivity can be conjectured. The manner is simple to operate, high in sensitivity, high in specificity, accurate in detection results, objective and quick, so that a clinician can be helped to clear the state of the endometrial receptivity, and the reagent kit can provide a basis for early diagnosis, target intervention and guidance of an embryo transplanting opportunity for infertility patients.

The invention relates to the field of medical technology, and particularly to a device for treating infertility, a system thereof and a method for performing body fluid regulation and neural channel and collateral regulation. The system performs body fluid regulation and neural channel and collateral regulation and settles an infertility problem caused by thin endometrium, low uterine receptivity,premature ovarian failure and low ovarian reserve function. Compared with prior art, The device, the system and the method according to the invention have advantages of realizing no physical invasion, no side effect and simple operation, improving human body fluid circulation, improving blood supply to reproductive organs such as pelvic cavity, uterus and ovary, improving nutrition supply and promoting generation of new blood vessels. The device, the system and the method according to the invention further have advantages of improving a human body reproduction endocrine system, improving hormone level, balancing an inner environment, and effectively treating infertility caused by thin endometrium, low uterine receptivity, premature ovarian failure and, ovarian reserve function, and furthermore can be used for auxiliary treatment before IVF-ET surgery.

The invention provides a method for evaluating endometrial receptivity of a patient and a kit for performing the method. According to the invention, the human endometrial receptivity functional statusis determined by using RNA or DNA sequencing (e.g., by NGS (next generation sequencing)) of a living tissue examination material from the endometrium, and using the expression of 248 genes related tothe endometrial receptivity status or a specific sub-combination thereof (as shown in Figure 1). Based on analysis, specific computational predictors classify samples according to their expression profiles in corresponding endometrial stages (proliferation stage, pre-receptive stage, early receptive stage, receptive stage, late receptive stage or post-receptive stage). It should be noted that thereceptivity statuses can be assigned through subsequent analysis of expression profiles of a specific gene set by the computational predictors.

The invention relates to a set of endometrial receptivity biomarkers, a kit and a method for judging endometrial receptivity. The biomarkers can provide an efficient, rapid, high-specificity and high-sensitivity detection and evaluation means for early discovery and diagnosis, targeted intervention and embryo transplantation guidance of PCOS infertility patients. The kit for detecting the PCOS endometrial receptivity contains the endometrial receptivity markers and can provide an efficient, rapid, high-specificity and high-sensitivity detection and evaluation means for early discovery and diagnosis of the PCOS infertility patients.

The invention provides application of a pharmaceutical composition in preparation of a medicine for preventing and/or treating thin endometrium or infertility. The pharmaceutical composition is a preparation prepared from the following raw material medicines in parts by weight of 7-13 parts of herba epimedii, 7-13 parts of rhizoma drynariae and 7-13 parts of herba cistanche. Experiments prove that after the pharmaceutical composition provided by the invention is taken, the endometrial receptivity of a thin endometrial (kidney-yang deficiency syndrome) patient is remarkably improved, the endometrial thickness, the female progestational hormone level in the middle stage of corpus luteum and the endometrial blood supply of the patient are remarkably improved, and the total effective rate of treatment is up to 87.88%. The pharmaceutical composition provided by the invention is precise and appropriate in compatibility, and has a wide prospect in preparation of medicines for preventing and/or treating kidney-yang deficiency type thin endometrium and thin endometrial infertility.

The invention provides compositions and methods for the use of oxytocin antagonists, such as substituted pyrrolidin-3-one oxime derivatives, among other compounds, in the treatment of subjects undergoing embryo transfer therapy. The compositions and methods of the invention can be used to dose subjects with oxytocin antagonists, including (3Z,55)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, among others, so as to improve endometrial receptivity and reduce the likelihood of embryo implantation failure and miscarriage following, for example, in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) embryo transfer procedures.

The invention discloses a traditional Chinese medicine composition for treating hypomenorrhea and infertility caused by thin endometrium and a preparation method thereof. The traditional Chinese medicine composition is prepared from 1-6 parts of roasted tortoise plastron, 1-6 parts of roasted turtle shell, 16 parts of prepared rehmannia root, 1-9 parts of pulp of dogwood fruit, 1-6 parts of parched white peony root, 0.5-3 part of fried angelica sinensis, 1-9 parts of ligusticum wallichii, 1.5-9 parts of spina date seed, 1-9 parts of roasted rhizoma anemarrhenae, 1-6 parts of poria cocos in Yunnan, 1-6 parts of fried codonopsis pilosula and 1-12 parts of roasted rhizoma atractylodis macrocephalae. A formula is screened through a large number of clinical researches, and a research result shows that the traditional Chinese medicine composition can effectively improve the syndromes of kidney yin deficiency type hypomenorrhea and infertility, increase the menorrhea, promote endometrial hyperplasia and follicle development in the later menstruation period, improve the levels of serum E2 and LH in the ovulation period, improve the levels of E2 and P in the middle luteal stage, increase the thickness of the endometrium in the middle-stage luteum, increase the volume of the endometrium and enrich blood perfusion under the endometrium in the middle-stage luteum, so that the endometrium receptivity is improved, embryo implantation is promoted to help pregnancy, and the traditional Chinese medicine composition is free of toxic and side effects and safe and reliable in medication.

The invention discloses a use of a traditional Chinese medicine composition in preparing a medicine for improving endometrial receptivity. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 10-20 parts of radix rehmanniae preparata, 10-20 parts of fructus corni, 10-20 parts of rhizoma dioscoreae, 10-20 parts of fructus lycii, 10-20 parts of semen cuscutae and 1-15 parts of deer-horn glue or cornu cervi degelatinatum. The traditional Chinese medicine composition of the invention can effectively improve endometrial receptivity and has a wide application prospect.

The invention belongs to the field of traditional Chinese medicines and relates to a compound medicine for improving gynecological reproductive endocrine diseases. The compound medicine is prepared from active ingredients and medicinal auxiliary materials, wherein the active ingredients consist of raw material cimicifuga rhizome, codonopsis pilosula, radix bupleuri, radix paeoniae rubrathe, radixpaeoniae alba, raw radix astragali, radix salviae miltiorrhizae, rhizoma ligustici wallichii, cortex moutan, radix puerariae, rhizoma cyperi, rhizoma corydalis, fructus toosendan, semen cuscutae, herba epimedii, dipsacus root or eucommia bark, acorus calamus and fructus aurantii. The compound medicine is prepared into granules, and animal experiments prove that the compound medicine can improve the thickness of endometrium and gland development of the mouse, improve the endometrial receptivity and regulate the HPO axis, and is suitable for improving gynecological diseases, such as recurrent abortion, infertility and the like, caused by low endometrial receptivity. The compound medicine can avoid inconvenience of temporary decoction and easy deterioration before the traditional Chinese medicine decoction is taken, and is convenient for patients.